Compare · DXCM vs HIND
DXCM vs HIND
Side-by-side comparison of DexCom Inc. (DXCM) and Vyome Holdings Inc. (HIND): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HIND operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 1770.3x HIND ($15.9M).
- Over the past year, DXCM is down 15.1% and HIND is down 88.2% - DXCM leads by 73.1 points.
- DXCM has been more active in the news (30 items in the past 4 weeks vs 2 for HIND).
- DXCM has more recent analyst coverage (25 ratings vs 0 for HIND).
- Company
- DexCom Inc.
- Vyome Holdings Inc.
- Price
- $72.74-0.92%
- $2.25-2.60%
- Market cap
- $28.08B
- $15.9M
- 1M return
- +21.17%
- +8.70%
- 1Y return
- -15.06%
- -88.20%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 30
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
Latest HIND
- Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Vyome Holdings Inc.
- Vyome Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
- Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
- SEC Form DEF 14A filed by Vyome Holdings Inc.
- Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
- SEC Form PRE 14A filed by Vyome Holdings Inc.
- SEC Form 10-K filed by Vyome Holdings Inc.
- Vyome Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits